Skip to main content
. 2017 Jun;102(6):1035–1043. doi: 10.3324/haematol.2017.163964

Figure 4.

Figure 4.

Kaplan-Meier estimates of overall survival (OS) depending on comparisons between multiple variables. (A) De novo mast cell leukemia (MCL) and secondary MCL (sMCL), (B) MCL with or without an associated hematologic neoplasm (AHN), (C) midostaurin treatment or cladribine (2-CDA) and/or midostaurin vice versa and (D) with mutations in the SRSF2/ASXL1/RUNX1 (S/A/Rpos) or without mutation in S/A/R (S/A/Rneg) gene panel. CI: confidence interval; HR: hazard ratio; NR: not reached.